Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers

• Benoit J. Arsenault,

  Affiliation Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

  ⨯
• Philip Barter,

  Affiliation The Heart Research Institute, Sydney, Australia

  ⨯
• David A. DeMicco,

  Affiliation Pfizer Inc, New York, NY, United States of America

  ⨯
• Weihang Bao,

  Affiliation Pfizer Inc, New York, NY, United States of America

  ⨯
• Gregory M. Preston,

  Affiliation Pfizer Inc, New York, NY, United States of America

  ⨯
• John C. LaRosa,

  Affiliation State University of New York Health Science Center, Brooklyn, NY, United States of America

  ⨯
• Scott M. Grundy,

  Affiliation University of Texas Southwestern Medical Center, Dallas, TX, United States of America

  ⨯
• Prakash Deedwania,

  Affiliation Veterans Affairs Central California Health Care System and University of California San Francisco School of Medicine, San Francisco, CA, United States of America

  ⨯
• Heiner Greten,

  Affiliation Universitätsklinikum, Eppendorf, Germany

  ⨯
• Nanette K. Wenger,

  Affiliation Emory University School of Medicine, Atlanta, GA, United States of America

  ⨯
• James Shepherd,

  Affiliation University of Glasgow, Glasgow, United Kingdom

  ⨯
• David D. Waters,

  Affiliation San Francisco General Hospital, San Francisco, CA, United States of America

  ⨯
• John J. P. Kastelein, for the Treating to New Targets (TNT) Investigators

  * E-mail: j.j.kastelein@amc.uva.nl

  Affiliation Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

  ⨯